Pacira Q3 revenue $168.6M, net loss $143.5M on $163.2M goodwill impairment; affirms FY guidance

Pacira BioSciences, Inc.

2024-Q3 EPS reported -$2.50 revenue$513,713,000

Revenue $168.6M; EXPAREL $132.0M (+2.6%), ZILRETTA $28.4M, iovera° $5.7M.
GAAP net loss $143.5M ($3.11/sh) on $163.2M goodwill impairment; non-GAAP net income $38.2M.
Adjusted EBITDA $54.7M; cash $453.8M. FY 2024 guidance reaffirmed ($680M-$705M rev).
CMS final rule confirms separate NOPAIN reimbursement for EXPAREL/iovera° starting Jan 1, 2025; new J-code J0666 effective same date.
Executive employment agreements amended for Gaugler, Slonin, Williams: enhanced severance (12-mo salary continuation; 18-mo on change of control).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.